REGENXBIO

REGENXBIO develops and licenses AAV vectors for retinal, neurological, and metabolic diseases. It offers a portfolio of capsids with broad or liver-biased tropism, differing from Nephrogen's AI-optimized kidney and pancreas-specific vehicles in both target tissue and discovery method.